RNS Number : 2128QBenchmark Holdings PLC16 February 2023

16 February 2023

Benchmark Holdings plc

("Benchmark" or the "Company")

Result of AGM

Benchmark Holdings plc, the aquaculture health, nutrition and genetics business, announces that at the Company's Annual General Meeting, held at 3.00 p.m. today, with the exception of Resolutions 15 and 16, all resolutions were passed by shareholders voting on a poll. The results of the poll are set out below.

Res No.

Resolution Name

Votes For

%

Votes Against

%

Votes Total

% I.S.C.

Votes Withheld

01

Reports and accounts

574,934,271

100.00%

8,379

0.00%

574,942,650

77.77

2,000

02

Remuneration Report

572,004,635

99.49%

2,938,015

0.51%

574,942,650

77.77

2,000

03

Reappoint Auditors

573,033,919

99.67%

1,908,731

0.33%

574,942,650

77.77

2,000

04

Auditors remuneration

574,925,589

100.00%

13,311

0.00%

574,938,900

77.77

5,750

05

Trond Williksen

574,934,271

100.00%

8,379

0.00%

574,942,650

77.77

2,000

06

Kristian Eikre

573,072,601

99.67%

1,870,049

0.33%

574,942,650

77.77

2,000

07

Septima Maguire

574,934,271

100.00%

8,379

0.00%

574,942,650

77.77

2,000

08

Peter George

571,410,678

99.39%

3,521,323

0.61%

574,932,001

77.77

12,649

09

Kevin Quinn

574,934,271

100.00%

8,379

0.00%

574,942,650

77.77

2,000

10

Susan Searle

573,072,601

99.67%

1,870,049

0.33%

574,942,650

77.77

2,000

11

Yngve Myhre

574,934,271

100.00%

8,379

0.00%

574,942,650

77.77

2,000

12

Atle Eide

573,068,851

99.67%

1,870,049

0.33%

574,938,900

77.77

5,750

13

Laura Lavers

573,068,851

99.67%

1,870,049

0.33%

574,938,900

77.77

5,750

14

Allot shares

571,916,971

99.47%

3,025,679

0.53%

574,942,650

77.77

2,000

15

pre-emption rights

258,462,999

44.95%

316,479,651

55.05%

574,942,650

77.77

2,000

16

Additional pre-emption rights

255,447,999

44.43%

319,494,651

55.57%

574,942,650

77.77

2,000

17

Purchase own shares

572,977,997

99.67%

1,898,423

0.33%

574,876,420

77.76

68,230

18

Cancel share premium account

574,935,897

100.00%

6,753

0.00%

574,942,650

77.77

2,000

The Board notes that Resolutions 15 (Disapplication of Pre-emption Rights - General) and 16 (Disapplication of Pre-emption Rights - Acquisitions and Specified Capital Investments), which were special resolutions requiring a 75% majority, did not receive sufficient support to be passed.

These resolutions were in line with the updated Pre-Emption Group's Statement of Principles and the Board considers the flexibility afforded by these authorities to be in the best interests of the Company.  In accordance with Provision 4 of the UK Corporate Governance Code, the Board confirms that it will consult and continue to engage with the relevant shareholders to understand and discuss their concerns with respect to these resolutions.

Enquiries

For further information, please contact:


Benchmark Holdings plc

Tel:  0114 240 9939

Ivonne Cantu, Investor Relations




Numis (Broker and NOMAD)

Tel:  020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith




MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare, Veronica Farah

[email protected]



About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.

Find out more at www.benchmarkplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDRAGUNRWROAUUAAR

==